Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati42

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati29

Views

Views
January 20251
February 20253
March 202515
April 20252
May 20250
June 20250
July 20258
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States8
Brazil2
Ecuador1
Spain1
United Kingdom1
Venezuela1
 

Top cities views

Views
Buffalo1
Caçapava1
Council Bluffs1
Guayaquil1
Hemet1
Lincoln Park1
Manila1
Pasadena1
Rio Grande1
San Bernardino1